Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

Objective: This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions. Methods: A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuyan Chen, PM (Author), Zhendong Fu, MM (Author), Xue Wen, MM (Author), Mingxia Zhang, PM (Author), Qiong Min, PM (Author), Peng Wang, PM (Author), Jin Zhang, MB (Author), Jun Ren, PM (Author), Wenbin Li, PD (Author), Rong Wang, PD (Author)
Format: Book
Published: Elsevier, 2024-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions. Methods: A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets, along with related literature was retrospectively analyzed. Results: Patients over 65 years old with a history of exposure to amiodarone may increase the incidence of pulmonary toxicity induced by dronedarone, and dronedarone should not be selected as a substitute treatment drug for patients with amiodarone-induced pulmonary toxicity. Conclusions: It is recommended that clinicians monitor the diffusion capacity of carbon monoxide and lung ventilation function of patients before and after using dronedarone for treatment. For patients with a history of amiodarone exposure, intermittent monitoring of chest X-rays and lung function is necessary. If lung function decreases, dronedarone should be immediately discontinued.
Item Description:0011-393X
10.1016/j.curtheres.2024.100743